Baiji Shenzhou (688235.SH): RoyaltyPharma agrees to pay $885 million at delivery to purchase the licensing fee for the use of the monoclonal antibody Imdelltra outside of China.

Zhixin Financial News APP News, BeiGene (688235.SH) announced that on August 25, 2025, the company and its wholly-owned subsidiary BeiGene Switzerland signed a "Royalty Purchase Agreement" with RoyaltyPharma. According to the agreement, RoyaltyPharma agreed to pay BeiGene Switzerland $885 million upon delivery, to purchase the majority of rights to the tiered calculation of an annual net revenue percentage from sales of any dose, form (including pegylated version), formulation (short-acting or long-acting), route of administration, or route of administration of the monoclonal antibody Imdelltra (Tarlatamab) in regions outside of China. The aforementioned royalty fees are fees that AstraZeneca pays to BeiGene Switzerland under the AstraZeneca Collaboration Agreement.